Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T13:53:51.115Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of bis(maltolato)oxovanadium (IV) (BMOV) on selenium nutritional status in diabetic streptozotocin rats

Published online by Cambridge University Press:  16 November 2011

Cristina Sanchez-Gonzalez ,
Carmen Bermudez-Peña ,
Fernando Guerrero-Romero ,
Cristina E. Trenzado ,
María Montes-Bayon ,
Alfredo Sanz-Medel  and
Juan Llopis
Cristina Sanchez-Gonzalez
Affiliation:
Institute of Nutrition and Food Technology and Department of Physiology, Campus Cartuja, University of Granada, E-18071Granada, Spain
Carmen Bermudez-Peña
Affiliation:
Biomedical Research Unit, Instituto Mexicano del Seguro Social, Victoria de Durango, Durango, Mexico
Fernando Guerrero-Romero
Affiliation:
Biomedical Research Unit, Instituto Mexicano del Seguro Social, Victoria de Durango, Durango, Mexico
Cristina E. Trenzado
Affiliation:
Departamento de Biología Animal, Facultad de Ciencias, Campus Fuentenueva, University of Granada, E-18071Granada, Spain
María Montes-Bayon
Affiliation:
Department of Analytical Chemistry, University of Oviedo, Oviedo, Spain
Alfredo Sanz-Medel
Affiliation:
Department of Analytical Chemistry, University of Oviedo, Oviedo, Spain
Juan Llopis*
Affiliation:
Institute of Nutrition and Food Technology and Department of Physiology, Campus Cartuja, University of Granada, E-18071Granada, Spain Instituto de Nutrición y Tecnología de Alimentos, Centro de Investigaciones Biomédicas, Laboratory 115, Universidad de Granada, Parque Tecnológico de la Salud, 18100 Armilla, Granada, Spain
*
*Corresponding author: Dr J. Llopis, fax +34 958 248959, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

The role of V as a micronutrient, and its hypoglycaemic and toxicological activity, have yet to be completely established. The present study focuses on changes in the bioavailability and tissue distribution of Se in diabetic streptozotocin rats following treatment with V. The following four study groups were examined: control; diabetic (DM); diabetic treated with 1 mg V/d (DMV); diabetic treated with 3 mg V/d (DMVH). V was supplied in the drinking water as bis(maltolato)oxovanadium (IV). The experiment had a duration of 5 weeks. Se was measured in food, faeces, urine, serum, muscle, kidney, liver and spleen. Glucose and insulin serum were studied, together with glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione transferase (GST) activity and malondialdehyde (MDA) levels in the liver. In the DM group, we recorded higher levels of food intake, Se absorbed, Se retained, Se content in the kidney, liver and spleen, GSH-Px and GST activity, in comparison with the control rats. In the DMV group, there was a significant decrease in food intake, Se absorbed, Se retained and Se content in the liver and spleen, and in GSH-Px and GST activity, while fasting glycaemia and MDA remained unchanged, in comparison with the DM group. In the DMVH group, there was a significant decrease in food intake, glycaemia, Se absorbed, Se retained, Se content in the kidney, liver and spleen, and in GSH-Px and GST activity, and increased MDA, in comparison with the DM and DMV groups. We conclude that under the experimental conditions described, the treatment with 3 mg V/d caused a tissue depletion of Se that compromised Se nutritional status and antioxidant defences in the tissues.

Keywords

VanadiumSeleniumDiabetesNutritional statusOxidative defence
Type
Full Papers
Information
British Journal of Nutrition , Volume 108 , Issue 5 , 14 September 2012 , pp. 893 - 899
Copyright
Copyright © The Authors 2011

Diabetes is a pathology that affects many metabolic processes, altering the concentration of various trace elements in the tissues, and of enzymes related to antioxidant defence. This circumstance, together with the metabolic changes induced by hyperglycaemia, may contribute to the development of the disease.

V is a widely distributed element, which is essential for some living organisms, but its role as a micronutrient, its essentiality, and its biological and pharmacological activity are as yet incompletely understood. Due to growing interest in the pharmacological effects of some V compounds, the metabolism of V is an important area of current investigation(Reference Thompson and Orvig1). In the plasma, V is present as 90 % bound to plasma proteins, primarily transferrin. Elsewhere, it is distributed primarily in the bone, kidney and liver. However, its interactions with other trace elements, regarding absorption and tissue distribution, are not well understood. Some complexes of V have been shown to possess hypoglycaemic effects, stimulating autophosphorylation of the insulin receptors and increasing the activity of tyrosine kinase, favouring the translocation of GLUT4(Reference Thompson and Orvig1, Reference Kawabe, Yoshikawa and Adichi2). It has been known that the V complex, bis(maltolato)oxovanadium (IV) (BMOV), is more effective than inorganic V as a glucose-lowering agent(Reference Thompson and Orvig1). Although some V complexes are currently undergoing human clinical trials(Reference Thompson and Orvig1), there are many aspects that remain to be determined, such as the digestive and metabolic interactions with other elements involved in antioxidant defence. According to some authors(Reference Thompson and Orvig1–Reference Yanardag and Tunail3), V improves glucose metabolism, and thus reduces the production of free radicals resulting from disorders in glucose metabolism; in consequence, it prevents oxidant damage caused by diabetes. However, others(Reference Oster, Llobet and Domingo4) have related V to pro-oxidant effects, because it does not normalise alterations in the metabolism of various trace elements, such as Fe, Zn and Cu, that are associated with diabetes.

In vitro and in vivo studies have shown that sodium selenate has an insulin-mimetic action similar to that of V, and that its administration to diabetic streptozotocin (STZ) rats produces hypoglycaemia(Reference Wiernsperger and Rapin5) by favouring the translocation of GLUT4 transporters in diabetic rats(Reference Xu, Yuan and Zou6). Moreover, Se is an element that is associated with antioxidant defence and protection against heavy metal toxicity(Reference Navarro-Alarcón and Cabrera-Vique7), a fact also observed in relation to diabetic rats(Reference Wiernsperger and Rapin5, Reference Erbayraktar, Yılmaz and Artmann8).

However, to date, no data have been published as to whether exposure to V might alter the metabolism of Se. For these reasons, we consider it important to address the present study of the interactions between V and Se in diabetic rats.

The aim of the present study is to examine whether V-treated diabetic rats experience alterations in the bioavailability and tissue distribution of Se, and in the activity of enzymes related to the nutritional status of Se and to antioxidant defence. The results obtained will reveal the existence, or otherwise, of interactions between these two elements and clarify the role of V as an anti-diabetic agent.

Materials and methods

Animals and diets

Male Wistar rats weighing 190–220 g (Charles River Laboratories, L′Arbresle, France) were randomly divided into four groups.

  1. (1) Control group (C): nine rats fed the semi-synthetic diet AIN-93. This diet provided 65 μg Se and 60 μg V/kg food.

  2. (2) Diabetic group (DM): eight rats fed the semi-synthetic diet AIN-93. Diabetes was induced in rats by the injection of STZ at a dose of 60 mg/kg.

  3. (3) Diabetic group treated with 1 mg V/d (DMV): ten rats fed the semi-synthetic diet AIN-93. Diabetes was induced in rats by the injection of STZ at a dose of 60 mg/kg. In addition, the rats in this group received in their drinking water 6·22 mg BMOV/d, which supplied 1 mg V/d.

  4. (4) Diabetic group treated with 3 mg V/d (DMVH): ten rats fed the semi-synthetic diet AIN-93. Diabetes was induced in rats by the injection of STZ at a dose of 60 mg/kg. In addition, the rats in this group received in their drinking water 18·66 mg BMOV/d, which supplied 3 mg V/d.

In all cases, the BMOV solution was prepared daily. During the experimental period, the weight gain and the intake of food and water were monitored. Every 7 d, the glucose level in the peripheral blood was analysed.

On day 35, rats were anaesthetised with a solution of pentobarbital (0·5 g/100 ml; Sigma-Aldrich, St Louis, MO, USA), and exsanguinated by cannulating the posterior aorta. Blood was collected and centrifuged (Beckman Coulter, Fullerton, CA, USA) at 3000 rpm for 15 min to separate serum. The gastrocnemius muscle, kidney, liver and spleen were also removed, weighed, placed in preweighed polyethylene vials and stored at − 80°C. During the last 7 d of the experimental period, the faeces and urine were collected every 24 h and stored at − 80°C in polyethylene bottles for subsequent analysis.

All animals were housed from day 0 of the experiment in individual metabolism cages designed for the separate collection of faeces and urine. The cages were located in a well-ventilated, temperature-controlled room (21 ± 2 °C) with relative humidity ranging from 40 to 60 %, and a light–dark period of 12 h.

The following biological indices were calculated: absorbed as (I − F), absorption (%) as ((I − F)/I) × 100, retained as (I − (F+U)) and retained (%) R/I as (I − (F+U))/I ×100, where I is the intake; F is the faecal excretion; U is the urinary excretion.

All experiments were carried out in accordance with Directional Guides Related to Animal Housing and Care (European Council Community, 1986) and all procedures were approved by the Animal Experimentation Ethics Committee of the University of Granada.

Analytical methods

Determination of V and Se in the diet, serum and tissues was performed using inductively coupled plasma spectroscopy–MS (Agilent 7500; Agilent Technologies, Tokyo, Japan). All materials used in the analysis were previously cleaned with super-pure HNO3 and ultra-pure water (18·2 Ω) obtained using a Milli Q system (Millipore, Bedford, MA, USA).

Samples were prepared by digestion with HNO3 and H2O2 (super-pure quality; Merck, Darmstadt, Germany), in a microwave digester (Milestone, Sorisole, Italy). When the sample had been digested, the extract was collected and made up to a final volume of 10 ml for subsequent analysis.

Calibration curves were prepared following the Ga addition technique as an internal standard, using stock solutions of 1000 mg/l of each element (Merck).

The total metal content (V and Se) in the tissues was analysed using inductively coupled plasma spectroscopy–MS techniques(Reference Del Castillo, Montes-Bayón and Añón9), and the accuracy of the method was evaluated by the analysis of suitable certified reference materials, Seronorm (Billingstad, Norway) and NIST 8414 (Gaithersburg, MD, USA), and by recovery studies in samples of organs enriched with multi-element standards. The percentage of CV obtained for Se was 2·9 % and that for V 5·6 %. For each element, we used the mean of five separate determinations of this reference material.

Glycaemia levels were determined using the sensor ACCU-CHEK AVIVA (Roche, Mannheim, Germany). Plasma levels of insulin were determined using the SPI BIO (Montigny le Bretonneux, France) enzyme immune assay technique.

Total antioxidant status (TAS) was determined using a Randox® assay kit (Randox Laboratories Limited, Crumlin, Antrim, UK). The assay is based on the incubation of 2,2′-azino-di-(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) with a peroxidase (methmyoglobin) and H2O2 to produce the radical cations ABTS+, which has a relatively stable blue-green colour, measured at 600 nm. The suppression of the colour is compared with that of Trolox, which is widely used as a traditional standard for TAS measurement assays, and the assay results are expressed as Trolox equivalent (nmol/l).

Liver samples were homogenised in ice-cold buffer (100 mm-Tris–HCl, 0·1 mm-EDTA and 0·1 % Triton X-100 (v/v), pH 7·8) at a ratio of 1:9 (w/v). Homogenates were centrifuged at 30 000 rpm for 30 min in a Centrikon H-401 (Kontron Hermle, Zurich, Switzerland) centrifuge. After centrifugation, the supernatant was collected and frozen at − 80°C until analysed.

All enzymatic assays were carried out at 25 ± 0·5°C using a PowerWavex microplate scanning spectrophotometer (Bio-Tek Instruments, Winooski, VT, USA) in duplicate in ninety-six-well microplates (UVStar®; Greiner Bio-One, Frickenhausen, Germany). The enzymatic reactions were started by the addition of the tissue extract. The specific assay conditions were as follows:

Glutathione peroxidase (GSH-Px; EC 1.11.1.9) activity was measured following the method of Flohé & Günzler(Reference Flohé and Günzler10) with some modifications(Reference Trenzado, Hidalgo and García-Gallego11). A freshly prepared glutathione reductase (GR) solution (40 μkat/l in 0·1 m-potassium phosphate buffer, pH 7·0) was added to a 50 mm-potassium phosphate buffer (pH 7·0), 0·5 mm-EDTA, 1 mm-sodium azide, 0·15 mm-NADPH and 0·15 mm-cumene hydroperoxide. After the addition of 1 mm- reduced glutathione (GSH), the NADPH consumption rate was monitored at 340 nm.

GR (EC 1.6.4.2) activity was assayed as described by Carlberg & Mannervik(Reference Carlberg and Mannervik12) with some modifications(Reference Trenzado, Hidalgo and García-Gallego11), by measuring the oxidation of NADPH at 340 nm. The reaction mixture consisted of 0·1 m-sodium phosphate buffer (pH 7·5), 1 mm-EDTA, 0·63 mm-NADPH and 0·15 mm-oxidised glutathione.

Glutathione transferase (GST; EC 2.5.1.18) activity was determined by the method of Habig et al. (Reference Habig, Pabst and Jakoby13) adapted to a microplate reader(Reference Sanz, Trenzado and López-Rodríguez14). The reaction mixture consisted of 0·1 m-phosphate buffer (pH 6·5), 1·2 mm-GSH and 1·23 mm-solution of 1-chloro-2,4-dinitrobenzene in ethanol, all prepared just before the assay. GST activity was monitored at 340 nm by the formation of glutathione–chloro-dinitro benzene conjugate.

For these enzymes, one unit of activity is defined as the amount of enzyme required to transform 1 μmol of substrate/min under the above assay conditions. The protein content of the supernatant solutions was determined by the Bradford method(Reference Bradford15), using bovine serum albumin as the standard.

Lipid peroxidation levels were determined based on malondialdehyde (MDA) levels generated by the oxidation of PUFA. In the presence of thiobarbituric acid, MDA reacts to produce coloured thiobarbituric-acid-reacting substances that were measured at 535 nm, following Buege & Aust(Reference Buege and Aust16).

The percentage of CV for GSH-Px, GR, GST and MDA was 7·3, 5·5, 6·4 and 8·5 %, respectively. For each enzyme, we used the mean of five separate determinations of the same liver sample from a control rat.

All biochemicals, including substrates, coenzymes and purified enzymes, were obtained from Roche or Sigma Chemical Company. All other chemicals came from Merck and were of reagent grade.

Statistical analysis

Descriptive statistical parameters (means and standard deviations) were obtained for each of the variables studied. The Mann–Whitney U test for two independent samples and the Kruskal–Wallis test for multiple independent samples were used in the analyses. For the bivariate analysis, Spearman's coefficient of correlation was calculated. All analyses were performed using SPSS 15.0 (SPSS, Chicago, IL, USA). Differences were considered statistically significant at a probability level < 5 %.

Results

Table 1 shows the evolution of the mean body weight and mean food intake of rats during the experimental period. The diabetic STZ rats (DM) did not present a significant change in body weight during the experimental period. Treatment with V, both at 1 mg V/d (DMV) and at 3 mg V/d (DMVH), induced weight changes similar to those observed in the DM rats.

Table 1 Evolution of mean body weight and mean food intakes during the experimental period

(Mean values with their standard errors)

C, control rats; DM, diabetic streptozotocin rats; DMV, diabetic streptozotocin rats treated with 1 mg V/d; DMVH, diabetic streptozotocin rats treated with 3 mg V/d.

Mean value was significantly different from that of the C group: * P < 0·05, ** P < 0·01, *** P < 0·001.

Mean value was significantly different from that of the DM group: † P < 0·05, ††† P < 0·001.

Mean value was significantly different from that of the DMV group: ‡ P < 0·05, ‡‡ P < 0·01, ‡‡‡ P < 0·001.

Diabetes increased the food intake. However, the higher-dose V treatment reduced the food intake of rats, to levels slightly below those of the control rats (Table 1).

Table 2 shows the evolution of fasting glycaemia during the experimental period. The V treatment of 1 mg/d did not significantly alter glycaemia levels in the diabetic rats during the first 28 d. However, on day 35, glycaemia levels were higher than those in the DM group. The treatment with the 3 mg V/d dose maintained glycaemia at levels similar to those of the control rats.

Table 2 Fasting glycaemia during the experimental period (mmol/l)

(Mean values with their standard errors)

C, control rats; DM, diabetic streptozotocin rats; DMV, diabetic streptozotocin rats treated with 1 mg V/d; DMVH, diabetic streptozotocin rats treated with 3 mg V/d.

Mean value was significantly different from that of the C group: * P < 0·05, ** P < 0·01, *** P < 0·001.

Mean value was significantly different from that of the DM group: † P < 0·05, †† P < 0·01.

Mean value was significantly different from that of the DMV group: ‡‡ P < 0·01, ‡‡‡ P < 0·001

Table 3 shows serum V, Se and insulin on day 35, in the experimental groups. Diabetes induced by STZ produced a significant increase in the serum levels of V and Se and a decrease in circulating insulin. The diabetic rats treated with 1 mg V/d did not present any change in serum Se or insulin, compared with the untreated diabetic rats. However, the diabetic rats treated with 3 mg V/d presented serum Se values below those of the control rats, while insulin and TAS remained at levels similar to those of the diabetic rats.

Table 3 Fasting selenium, vanadium and insulin in serum on day 35

(Mean values with their standard errors)

** Mean value was significantly different from that of the C group (P < 0·01).

†† Mean value was significantly different from that of the DM group (P < 0·01).

‡‡ Mean value was significantly different from that of the DMV group (P < 0·01).

Table 4 shows the digestive and metabolic utilisation of Se. Diabetes (DM group) increases the net values of absorbed and retained Se; although when expressed as a percentage (% absorption and %R/I), no significant changes were observed. The diabetic rats treated with 1 mg V/d (DMV) presented a reduction in Se absorption and Se retained, in comparison with the DM group.

Table 4 Digestive and metabolic utilisation of selenium on days 28–35 of the study

(Mean values with their standard errors)

C, control rats; DM, diabetic streptozotocin rats; DMV, diabetic streptozotocin rats treated with 1 mg V/d; DMVH, diabetic streptozotocin rats treated with 3 mg V/d; I, intake; F, faecal excretion; U, urinary excretion; A, absorbed; R, retained.

Mean value was significantly different from that of the C group: * P < 0·05, ** P < 0·01, *** P < 0·001.

Mean value was significantly different from that of the DM group: †P < 0.05, ††P < 0.01, †††P < 0.001.

Mean value was significantly different from that of the DMV group: ‡P < 0·05, ‡‡P < 0·01, ‡‡‡P < 0·001.

Table 5 shows the Se content in the muscle, kidney, liver and spleen on day 35. Diabetes increased Se content in the kidney, liver, spleen and heart. In the diabetic rats, the V treatment, at a dose of 1 mg V/d, decreased Se content in the liver and spleen in comparison with the untreated diabetic rats (DM), but these values remained higher than those of the control rats, except in the case of the muscle and spleen. The treatment of the diabetic rats with 3 mg V/d produced a significant reduction in Se in the kidney, liver and spleen.

Table 5 Selenium content in muscle, kidney, liver, spleen, heart, adipose tissue and femur (mg/kg dry tissue) on day 35

(Mean values with their standard errors)

C, control rats; DM, diabetic streptozotocin rats; DMV, diabetic streptozotocin rats treated with 1 mg V/d; DMVH, diabetic streptozotocin rats treated with 3 mg V/d.

Mean value was significantly different from that of the C group: * P < 0·05, ** P < 0·01, *** P < 0·001.

Mean value was significantly different from that of the DM group: †P < 0·05, ††P < 0.01 †††P < 0·001.

Mean value was significantly different from that of the DMV group: ‡P < 0·05, ‡‡‡P < 0·001.

TAS and the activities of GSH-Px, GR, GST and lipid peroxidation levels (MDA) are shown in Table 6. The treatment leads to a decrease in the activity of GSH-Px and GST and an increase in the lipid peroxidation level.

Table 6 Total antioxidant status (TAS) in serum and activity of glutathione peroxidase (GSH-Px); glutathione reductase (GR) and glutathione transferase (GST), and malondialdehyde (MDA) levels in the liver on day 35

(Mean values with their standard errors)

C, control rats; DM, diabetic streptozotocin rats; DMV, diabetic streptozotocin rats treated with 1 mg V/d; DMVH, diabetic streptozotocin rats treated with 3 mg V/d.

Mean value was significantly different from that of the C group: * P < 0·05, ** P < 0·01, *** P < 0·001.

Mean value was significantly different from that of the DM group: ††P < 0·01, †††P < 0·001.

Mean value was significantly different from that of the DMV group: ‡P < 0·05, ‡‡‡P < 0·001.

The bivariate study revealed the existence of significant relationships, among which the following are particularly important: V intake correlated negatively with Se absorbed (r − 0·556; P < 0·01), Se retained (r − 0·644; P < 0·001), GSH-Px (r − 0·414; P < 0·05) and GST (r − 0·817; P < 0·001) activity, and positively with MDA (r 0·388; P < 0·05).

Se intake correlated positively with Se content in the kidney (r 0·790; P < 0·001), liver (r 0·840; P < 0·001), spleen (r 0·593; P < 0·001) and heart (r 0·529; P < 0·01). Se absorbed correlated positively with the serum levels of Se (r 0·870; P < 0·001), Se content in the kidney (r 0·876; P < 0·001), liver (r 0·880; P < 0·001), spleen (r 0·664; P < 0·001) and heart (r 0·420; P < 0·05). Se content in the liver correlated positively with GSH-Px (r 0·941; P = 0·001) and negatively with MDA (r − 0·529; P < 0·01).

Discussion

Diabetes is a pathology that affects the metabolism of various trace elements and the activity of enzymes related to antioxidant defence. This circumstance may contribute to the development of the disease. It has been shown that V is a trace element associated with the regulation of glucose, improving its transport and metabolism and increasing the sensitivity of the insulin receptor(Reference Thompson and Orvig1). However, there are many aspects that remain to be determined, such as the interactions with other elements.

In view of the lack of information on Se–V interactions, the present study examines diabetic rats treated with different doses of V in order to determine Se bioavailability and tissue distribution, and its relationship to some indicators of the nutritional status of this element. Based on the study results, under our experimental conditions, the V treatment caused a tissue depletion of Se that compromised Se nutritional status and antioxidant defences in the tissues

The doses of V used in the present study (1 mg V/d approximately 5 mg V/kg body weight per d and 3 mg V/d approximately 15 mg V/kg body weight per d) are higher than the lowest dose reported to cause adverse effects in rats (0·8 mg V/kg body weight per d). However, the doses used are low in comparison with those used in other studies and much lower than LD50 (lethal close 50) (40–90 mg V/kg body weight per d)(17). In each group treated with V, two rats (20 %) were removed from the present study due to gastrointestinal disorders.

In the untreated diabetic rats (DM), there were no significant weight increases during the experimental period, due to the hypercatabolism that accompanies the disease, although the rats presented polyphagia. The diabetic rats treated with V did not present significant weight changes(Reference Oster, Llobet and Domingo4), although food intake did significantly decrease as the V dose was increased, reaching values similar to those of the control rats in the case of the dose of 3 mg V/d. It has been suggested that the decrease in food intake could be because V heightens the catabolic effects of leptin, favouring body-weight loss and reducing food intake(Reference Wilsey, Mantheny and Scarpace18).

The V treatment of 1 mg/d (DMV) did not significantly alter glycaemia levels in the diabetic rats during the first 28 d. The higher levels of glycaemia observed on day 35 in the DMV group, with respect to the DM group, could be because STZ produced more severe pancreatic damage in some rats, and this circumstance was apparent at the end of the experimental period.

The dose of 3 mg V/d normalised glycaemia levels in the diabetic rats, from the first week of the treatment. These results coincide with those reported earlier(Reference Majithiya, Balaraman and Giridhar19–Reference Cam, Rodrigues and McNeill21). Nevertheless, other authors have observed that although V exercises a hypoglycaemic effect, normal glycaemia levels are not achieved(Reference Yanardag and Tunail3, Reference Oster, Llobet and Domingo4, Reference Facchini, Yuen and Batell22, Reference Tas, Sarandol and Ayvalik23). This inconsistency could be due to various factors, such as the use of different compounds and doses of V, the duration of assays, the method employed to determine glucose levels, the dose of STZ used and/or variability in the animals' responses.

The diabetic rats presented a level of insulinaemia that was well below that observed in the control rats, due to the destruction of β-cells caused by STZ. Treatment with V, independently of the dose applied, had no effect on the serum levels of insulin (Table 3).

Serum levels of Se in the DM group were higher than those in the control group, because the animals in the DM group consumed more food, which led to increases in the net quantities of Se absorbed and retained (Table 4). The increased body retention of Se caused by diabetes is assumed to be responsible for the increased serum levels and the content of Se in the tissues of the diabetic rats (Table 5). The correlations found between Se intake and its content in the tissues (see the Results section) corroborate this hypothesis.

The treatment of the diabetic rats with 1 mg V/d (DMV group) had no effect on fasting glycaemia, but in comparison with the untreated diabetic rats, there was a decrease in food intake and in the net quantities of Se absorbed and retained. In our opinion, the lower absorption and retention of Se in the DMV group appears to respond to the changes in food intake produced by the treatment. The reduced Se retention is responsible for the slight decrease in Se content in the liver and spleen.

The dose of 3 mg V/d given to the diabetic rats (DMVH group) had a clearly anti-diabetic effect, normalising glycaemia levels and reducing food intake to levels similar to those of the controls. Moreover, this dose of V produced a severe reduction in the absorption and urinary losses of Se. We believe that the main cause of the drastic reduction in absorbed Se may be due to reduced Se intake (Table 3). Nevertheless, the high concentration of V in the intestine could also have interfered with Se absorption(Reference Arduser, Wolffram and Scharrer24, Reference Nielsen, Ziegler and Filder25). The negative correlations found between the intake of V and the absorbed Se (see the Results section) corroborate the above remarks.

The reduction in the urinary losses of Se could be a compensatory mechanism to avoid its depletion. Under physiological conditions, the homoeostasis of Se is basically regulated by urinary excretion(Reference Navarro-Alarcón and Cabrera-Vique7, Reference Gammelgaard, Gabel-Jensen and Stürup26).

We believe that in the DMVH group, the reduced absorption is responsible for the lower Se content in serum (Table 3) and in the kidney, liver and spleen (Table 5).

In order to better determine whether Se tissue depletion had affected the oxidative status, we designed a study of serum TAS and of the activity of three GSH-dependent enzymes: GSH-Px and hepatic GR and GST.

The present results show that in the untreated diabetic rats, serum TAS decreased, while in the liver, the activity of GSH-Px increased, that of GR remained unchanged and that of GST diminished (Table 6). The increased GSH-Px activity could be related to the greater content of hepatic Se found in this group. Hepatic GSH-Px is known to be very effective in determining the nutritional status of Se(Reference Hafeman, Sunde and Hoekstra27) (Table 5). An earlier publication has reported lower levels of GSH in the erythrocytes of diabetic patients(Reference Lei, Cheng and McClung28). In the present study conditions, the degradation of GSH would account for the reduced activity of GST found in this group.

The V treatment given to the diabetic rats did not affect TAS (Table 6), irrespective of the dose. Other authors, in previous studies(Reference Scibior, Zaporowska and Wolinska29), have observed no significant changes in TAS following the V treatment.

It has been reported that exposure to V results in the depletion of the cellular GSH pool, which increases the vulnerability to lipid peroxidation(Reference Valko, Morris and Cronin30–Reference Cuesta, Francés and García32). The results obtained in the present study show that the V treatment to the diabetic rats at 1 mg V/d does not modify glycaemia, but does produce slight decreases in food intake, Se absorbed and Se in the liver and spleen. The depletion of Se in the liver is accompanied by a reduction in the activity of GSH-Px and a non-significant increase in MDA, compared with the untreated diabetic rats. The treatment at 3 mg V/d induced a clearly anti-diabetic effect, as both food intake and glycaemia levels were normalised. In addition, there was a sharp decrease in Se absorption and Se content in various tissues. The strong depletion of Se in the liver (Table 5) could account for the reduced activity of GSH-Px. Studies(Reference Oster, Llobet and Domingo4, Reference Bycczkowski, Kulkarni and Nriagu31) have reported that the depletion of GSH could account for the reduced activity of GST and also contribute to that of GSH-Px. The lower levels of activity of these enzymes could be related to the higher levels of MDA. Bivariate analysis reveals a high positive correlation between the liver content of Se and the activity of GSH-Px, together with a negative correlation with MDA (see the Results section). We conclude that under our experimental conditions, the V treatment caused a tissue depletion of Se that compromised Se nutritional status and antioxidant defences in the tissues. However, further studies are needed to better determine the effects arising from these interactions.

Acknowledgements

The authors are grateful for support received from the Consejería de Innovacion, Ciencia y Empresa, Andalusian Regional Government (project P06-CTS-01435). All authors have made substantial contributions to all of the following: the conception and design of the study, or acquisition of the data, or analysis and interpretation of the data; drafting the manuscript or revising it critically for important intellectual content; final approval of the version to be submitted. There are no conflicts of interest of authors or consortium members, since this study was funded by public funds. This study is dedicated to basic research and there are no commercial interests.

References

1Thompson, KH & Orvig, C (2006) Vanadium in diabetes: 100 years from Phase 0 to Phase I. J Inorg Biochem 100, 1925–1935.CrossRefGoogle Scholar
2Kawabe, K, Yoshikawa, Y, Adichi, et al. (2006) Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. Life Sci 78, 2860–2866.CrossRefGoogle ScholarPubMed
3Yanardag, R & Tunail, S (2006) Vanadyl sulphate administration protects the streptozotocin-induced oxidative damage to brain tissue in rats. Mol Cell Biochem 286, 153–159.CrossRefGoogle ScholarPubMed
4Oster, MH, Llobet, JM, Domingo, LJ, et al. (1993) Vanadium treatment of diabetic Sprague–Dawley rats results in tissue vanadium accumulation and pro-oxidant effects. Toxicology 83, 115–130.CrossRefGoogle ScholarPubMed
5Wiernsperger, N & Rapin, JR (2010) Trace elements in glucometabolic disorders: an update. Diabetol Metab Syndr 2, 70–75.CrossRefGoogle ScholarPubMed
6Xu, TJ, Yuan, BX, Zou, YM, et al. (2010) The effect of insulin in combination with selenium on blood glucose and GLUT4 expression in the cardiac muscle of streptozotocin-induced diabetic rats. Fundam Clin Pharmacol 24, 199–204.CrossRefGoogle ScholarPubMed
7Navarro-Alarcón, M & Cabrera-Vique, C (2008) Selenium in food and the human body: a review. Sci Total Environ 400, 115–141.CrossRefGoogle ScholarPubMed
8Erbayraktar, Z, Yılmaz, O, Artmann, AT, et al. (2007) Effects of selenium supplementation on antioxidant defense and glucose homeostasis in experimental diabetes mellitus. Biol Trace Elem Res 118, 217–226.CrossRefGoogle ScholarPubMed
9Del Castillo, E, Montes-Bayón, M, Añón, E, et al. (2008) Simultaneous determination of glycated haemoglobin, a long term biomarker of diabetes mellitus, and total haemoglobin by isotope dilution and HPLC–ICP–MS. J Anal At Spectrom 23, 758–764.CrossRefGoogle Scholar
10Flohé, L & Günzler, LWA (1984) Assay of glutathione peroxidase. Meth Enzymol 105, 115–121.Google ScholarPubMed
11Trenzado, CE, Hidalgo, MC, García-Gallego, M, et al. (2006) Antioxidant enzymes and lipid peroxidation in sturgeon Acipenser naccarii and trout Oncorhynchus mykiss. A comparative study. Aquaculture 254, 758–767.CrossRefGoogle Scholar
12Carlberg, I & Mannervik, B (1975) Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J Biol Chem 250, 5475–5480.CrossRefGoogle ScholarPubMed
13Habig, WH, Pabst, MJ & Jakoby, WB (1974) Glutathione S-transferases – the first enzymatic step in mercapturic acid formation. J Biol Chem 249, 7130–7139.CrossRefGoogle ScholarPubMed
14Sanz, A, Trenzado, CE, López-Rodríguez, MJ, et al. (2010) Study of antioxidant defense in four species of Perloidea (Insecta, Plecoptera). Zoolog Sci 27, 952–958.CrossRefGoogle ScholarPubMed
15Bradford, MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 72, 248–256.CrossRefGoogle Scholar
16Buege, JA & Aust, SD (1978) Microsomal lipid peroxidation. Meth Enzymol 52, 302–310.CrossRefGoogle ScholarPubMed
17EFSA (2004) Opinion of the scientific panel on dietetic products, nutrition and allergies on a request from the commission related to the tolerable upper intake level of vanadium (request no. EFSA-Q-2003-018). EFSA J 33, 1–22. http://www.efsa.eu.int/.Google Scholar
18Wilsey, J, Mantheny, MK & Scarpace, PJ (2006) Oral vanadium enhances the catabolic effects of central leptin in young adult rats. Endocrinology 147, 493–501.CrossRefGoogle ScholarPubMed
19Majithiya, JB, Balaraman, R, Giridhar, R, et al. (2005) Effect of bis[curcumino]oxovanadium on non-diabetic and streptozotocin-induced diabetic rats. J Trace Elem Med Biol 18, 211–217.CrossRefGoogle Scholar
20Sun Qian, , Sekar, N, Goldwaser, I, et al. (2000) Vanadate restores glucose-6-phosphate in diabetic rats: a mechanism to enhance glucose metabolism. Am J Physiol Endocrinol Metab 279, 403–410.Google Scholar
21Cam, M, Rodrigues, B & McNeill, JH (1999) Distinct glucose lowering and beta cell protective effects of vanadium and food restriction in streptozotocin-diabetes. Eur J Endocrinol 141, 546–554.CrossRefGoogle ScholarPubMed
22Facchini, DM, Yuen, VG, Batell, ML, et al. (2006) The effects of vanadium treatment on bone in diabetic and non-diabetic rats. Bone 38, 368–377.CrossRefGoogle Scholar
23Tas, S, Sarandol, E, Ayvalik, SZ, et al. (2007) Vanadyl sulphate, taurine, and combined vanadyl sulphate and taurine treatments in diabetic rats: effects on the oxidative and antioxidative systems. Arch Med Res 38, 276–283.CrossRefGoogle ScholarPubMed
24Arduser, F, Wolffram, S & Scharrer, E (1985) Active absorption of selenate by ileum. J Nutr 115, 1203–1208.CrossRefGoogle ScholarPubMed
25Nielsen, FH (1996) Other trace elements. Vanadium. In Present Knowledge in Nutrition, pp. 364–370 [Ziegler, EE and Filder, LJ, editors]. Washington, DC: ILSI Press.Google Scholar
26Gammelgaard, B, Gabel-Jensen, C, Stürup, S, et al. (2008) Complementary use of molecular and element-specific mass spectrometry for identification of selenium compounds related to human selenium metabolism. Anal Bioanal Chem 390, 1691–1706.CrossRefGoogle ScholarPubMed
27Hafeman, DG, Sunde, RA & Hoekstra, WG (1974) Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J Nutr 104, 580–587.CrossRefGoogle ScholarPubMed
28Lei, XG, Cheng, W-H & McClung, JP (2007) Metabolic regulation and function of glutathione peroxidase-1. Ann Rev Nutr 27, 41–61.CrossRefGoogle ScholarPubMed
29Scibior, A, Zaporowska, H, Wolinska, A, et al. (2010) Antioxidant enzyme activity and lipid peroxidation in the blood of rats co-treated with vanadium (V+5) and chromium (Cr+3). Cell Biol Toxicol 26, 509–526.CrossRefGoogle ScholarPubMed
30Valko, M, Morris, H & Cronin, MTD (2005) Metals, toxicity and oxidative stress. Curr Med Chem 12, 1161–1208.CrossRefGoogle ScholarPubMed
31Bycczkowski, JZ & Kulkarni, AP (1998) Oxidative stress and pro-oxidant biological effects of vanadium. In Vanadium in the Environment. Part 2: Health Effects, pp. 235–264 [Nriagu, JO, editor]. New York: John Wiley, Sons, Inc.Google Scholar
32Cuesta, S, Francés, D & García, GB (2010) ROS formation and antioxidant status in brain areas of rats exponed to sodium metavanadate. Neurotoxicol Teratol 33, 297–302.CrossRefGoogle Scholar
Figure 0

Table 1 Evolution of mean body weight and mean food intakes during the experimental period(Mean values with their standard errors)

Figure 1

Table 2 Fasting glycaemia during the experimental period (mmol/l)(Mean values with their standard errors)

Figure 2

Table 3 Fasting selenium, vanadium and insulin in serum on day 35(Mean values with their standard errors)

Figure 3

Table 4 Digestive and metabolic utilisation of selenium on days 28–35 of the study(Mean values with their standard errors)

Figure 4

Table 5 Selenium content in muscle, kidney, liver, spleen, heart, adipose tissue and femur (mg/kg dry tissue) on day 35(Mean values with their standard errors)

Figure 5

Table 6 Total antioxidant status (TAS) in serum and activity of glutathione peroxidase (GSH-Px); glutathione reductase (GR) and glutathione transferase (GST), and malondialdehyde (MDA) levels in the liver on day 35(Mean values with their standard errors)